{"title":"接受免疫检查点抑制剂治疗的癌症患者关节痛：一项系统综述和荟萃分析。","authors":"Yoshito Nishimura, Jonathan Estaris, Mako Koseki, Evelyn Elias, Fnu Chesta, Kensuke Takaoka, Theresa Shao, Nobuyuki Horita, Yu Fujiwara","doi":"10.1080/1750743X.2025.2501519","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Although immune checkpoint inhibitors (ICIs) are widely used for patients with cancer, evidence of the impact of ICIs on the incidence of arthralgia remains limited.</p><p><strong>Objective: </strong>To evaluate the impact of ICIs on arthralgia incidences in patients with cancer.</p><p><strong>Methods: </strong>We performed a systematic review to identify phase 3 randomized control trials (RCTs) evaluating ICIs in patients with cancer and reporting the incidence of arthralgia. We performed a meta-analysis to pool odds ratios (ORs) of any grade and grade 3-5 arthralgia.</p><p><strong>Results: </strong>Forty RCTs (<i>n</i> = 26,610) were included. The incidence of any-grade and grade 3-5 treatment-related arthralgia was 12.0% (<i>n</i> = 1,125/9,395) and 0.54% (<i>n</i> = 47/8,723). The addition of an ICI to systemic therapy, such as chemotherapy, significantly increased any-grade (OR 1.32, 95% CI: 1.13-1.54, <i>p</i> = 0.001) and grade 3-5 arthralgia (OR 1.78, 95% CI: 1.08-2.94, <i>p</i> = 0.02) with low heterogeneity among ICI subtype subgroups (<i>I</i><sup>2</sup> = 0%). ICI monotherapy was associated with higher incidences of arthralgia than non-taxane (OR 6.83, 95% CI: 3.05-15.30, <i>p</i> < 0.001) but not than taxane chemotherapy (OR 0.74, 95% CI: 0.44-1.24, <i>p</i> = 0.25).</p><p><strong>Conclusions: </strong>These results could guide oncologists to assess arthralgia in patients receiving ICIs.</p>","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"437-446"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12091910/pdf/","citationCount":"0","resultStr":"{\"title\":\"Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.\",\"authors\":\"Yoshito Nishimura, Jonathan Estaris, Mako Koseki, Evelyn Elias, Fnu Chesta, Kensuke Takaoka, Theresa Shao, Nobuyuki Horita, Yu Fujiwara\",\"doi\":\"10.1080/1750743X.2025.2501519\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Although immune checkpoint inhibitors (ICIs) are widely used for patients with cancer, evidence of the impact of ICIs on the incidence of arthralgia remains limited.</p><p><strong>Objective: </strong>To evaluate the impact of ICIs on arthralgia incidences in patients with cancer.</p><p><strong>Methods: </strong>We performed a systematic review to identify phase 3 randomized control trials (RCTs) evaluating ICIs in patients with cancer and reporting the incidence of arthralgia. We performed a meta-analysis to pool odds ratios (ORs) of any grade and grade 3-5 arthralgia.</p><p><strong>Results: </strong>Forty RCTs (<i>n</i> = 26,610) were included. The incidence of any-grade and grade 3-5 treatment-related arthralgia was 12.0% (<i>n</i> = 1,125/9,395) and 0.54% (<i>n</i> = 47/8,723). The addition of an ICI to systemic therapy, such as chemotherapy, significantly increased any-grade (OR 1.32, 95% CI: 1.13-1.54, <i>p</i> = 0.001) and grade 3-5 arthralgia (OR 1.78, 95% CI: 1.08-2.94, <i>p</i> = 0.02) with low heterogeneity among ICI subtype subgroups (<i>I</i><sup>2</sup> = 0%). ICI monotherapy was associated with higher incidences of arthralgia than non-taxane (OR 6.83, 95% CI: 3.05-15.30, <i>p</i> < 0.001) but not than taxane chemotherapy (OR 0.74, 95% CI: 0.44-1.24, <i>p</i> = 0.25).</p><p><strong>Conclusions: </strong>These results could guide oncologists to assess arthralgia in patients receiving ICIs.</p>\",\"PeriodicalId\":13328,\"journal\":{\"name\":\"Immunotherapy\",\"volume\":\" \",\"pages\":\"437-446\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12091910/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/1750743X.2025.2501519\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2025.2501519","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Background: Although immune checkpoint inhibitors (ICIs) are widely used for patients with cancer, evidence of the impact of ICIs on the incidence of arthralgia remains limited.
Objective: To evaluate the impact of ICIs on arthralgia incidences in patients with cancer.
Methods: We performed a systematic review to identify phase 3 randomized control trials (RCTs) evaluating ICIs in patients with cancer and reporting the incidence of arthralgia. We performed a meta-analysis to pool odds ratios (ORs) of any grade and grade 3-5 arthralgia.
Results: Forty RCTs (n = 26,610) were included. The incidence of any-grade and grade 3-5 treatment-related arthralgia was 12.0% (n = 1,125/9,395) and 0.54% (n = 47/8,723). The addition of an ICI to systemic therapy, such as chemotherapy, significantly increased any-grade (OR 1.32, 95% CI: 1.13-1.54, p = 0.001) and grade 3-5 arthralgia (OR 1.78, 95% CI: 1.08-2.94, p = 0.02) with low heterogeneity among ICI subtype subgroups (I2 = 0%). ICI monotherapy was associated with higher incidences of arthralgia than non-taxane (OR 6.83, 95% CI: 3.05-15.30, p < 0.001) but not than taxane chemotherapy (OR 0.74, 95% CI: 0.44-1.24, p = 0.25).
Conclusions: These results could guide oncologists to assess arthralgia in patients receiving ICIs.
期刊介绍：
Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field.
Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
